Medical devices, healthcare technology and the business of care
510(k) clearance · K262597

Access BNP II

BECKMAN COULTER, INC. · Decision date Oct 20, 2026

MEDTECHLEDGER EXPLANATIONK262597

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on October 20, 2026 for Access BNP II, a 510(k) submitted by Beckman Coulter, Inc. of Chaska, Minnesota under K262597. The device is classified as a B-type natriuretic peptide test system under 21 CFR 862.1117, Class II, product code NBC, with Clinical Chemistry as the regulation medical specialty and review panel. The application was received July 27, 2026 and reviewed as a traditional 510(k) without third-party review; it was not a combination product and no predetermined change control plan was authorized.

SESE denotes clearance to market, not premarket approval. The available excerpts do not state the specific assay components, intended-use wording, or performance data supporting the determination, and the decision summary itself was not captured in the source excerpts. The FDA letter notes general controls obligations such as registration and listing, labeling, and good manufacturing practice, but the excerpted text is truncated. Any reading of clinical utility or labeling claims beyond the recorded classification would require the full decision documents.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Clinical Chemistry
Decision date
Oct 20, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K262597
Regulatory pathway
510(k) premarket notification
Product code
NBC
Decision code
SESE
Decision date
Oct 20, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Test, Natriuretic Peptide.

Product code
NBC
FDA device class
2

FDA decision timeline

  1. K262597 received

    Application receipt date recorded by FDA.

  2. K262597 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code NBC

Product / regulatory recordCompanyPathwayDecision dateSource
BECKMAN COULTER, INC.510(k) clearanceSep 21, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

BECKMAN COULTER, INC.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Chaska, MN

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records